Humana Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.67%.
Did HUM Beat Earnings? Q2 2025 Results
Humana posted a strong second quarter, with adjusted EPS of $6.27 beating the $5.87 consensus estimate by 6.87% and revenue of $32.39 billion topping expectations by 1.69% on 9.6% year-over-year growth, offering a measure of reassurance to investors in a sector battered by rising medical costs and profit warnings from several peers. The key driver behind the beat was a 89.9% Insurance segment benefit ratio that landed in line with management's own target, reflecting favorable Medicare Advantage pricing and Part D seasonality dynamics that helped offset a mix shift toward higher-cost state-based contracts. Individual Medicare Advantage membership declines also proved less severe than feared, with year-to-date attrition of approximately 432,500, better than the previously guided 550,000. Buoyed by the results, Humana raised its full-year adjusted EPS guidance to approximately $17.00 from $16.25, lifted consolidated revenue guidance to at least $128 billion, and increased its CenterWell net patient growth target to 50,000 to 70,000, signaling growing confidence in the diversified care delivery business.
- Higher per member Medicare premiums driven by increased direct subsidy due to the Inflation Reduction Act (IRA)
- Membership growth in state-based contracts and stand-alone PDP businesses
- CenterWell outperformance driven by higher-than-anticipated specialty pharmacy script volumes and favorable drug mix
- Better-than-expected individual Medicare Advantage membership retention with 43% recapture of members impacted by plan exits
- Individual Medicare Advantage pricing inclusive of plan exits and benefit design changes more than offsetting claims trend
- Administrative cost efficiencies from value creation initiatives
- CenterWell Primary Care patient growth of 10% year-to-date with improved Net Promoter Score up 250 basis points year over year
- Acute admissions and observations per thousand decreased 600 basis points year over year in staffed centers
“We feel good about our solid performance in the first half of the year. It reinforces our strategy to continue investing in improved outcomes, operational excellence and a better experience for our customers and investors.”
Humana CEO, on the earnings call
Forward Guidance & Outlook
Humana raised FY 2025 Adjusted EPS guidance to 'approximately $17.00' from 'approximately $16.25' and revised GAAP EPS guidance to 'approximately $13.77' from 'approximately $14.68'. Consolidated revenue guidance was raised to 'at least $128 billion' from a prior range of $126–$128 billion. Insurance segment revenue guidance raised to 'at least $123 billion'. Individual Medicare Advantage membership decline improved to 'up to 500,000' from 'approximately 550,000'. Insurance segment benefit ratio guidance affirmed at 90.1%–90.5%. CenterWell segment revenue guided to 'at least $21.5 billion'. Insurance segment income from operations guided to $1.6–$2.0 billion GAAP. CenterWell segment income from operations guided to $1.1–$1.5 billion GAAP ($1.3–$1.7 billion non-GAAP). FY 2025 operating cash flows guided to $2.4–$2.9 billion. Capital expenditures approximately $650 million. Effective tax rate approximately 25%. Third quarter earnings expected to be approximately 15%–20% of FY 2025 Adjusted earnings with 3Q Insurance segment benefit ratio expected just above 91%. Management committed to achieving individual MA pretax margin of 'at least 3%' over time.
HUM YoY Financials
HUM Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.